Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

F. Crippa, G. L. Buraggi, E. Di Re, M. Gasparini, E. Seregni, S. Canevari, M. Gadina, M. Presti, A. Marini, E. Seccamani

Research output: Contribution to journalArticlepeer-review


The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.

Original languageEnglish
Pages (from-to)724-729
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number6
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody'. Together they form a unique fingerprint.

Cite this